drugset / Trial / NCT06068400
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma
Terminated
1 enrolled
Guangzhou Bio-gene Technology Co., Ltd
Shenzhen Nanshan District Shekou People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, single center clinical study evaluating the safety and efficacy of CAR-T treatment for relapsed or refractory multiple myeloma.
Timeline
- Start
- 2023-09-21
- Primary completion
- 2024-02-02
- Completion
- 2024-02-02
Outcome
Outcome not reported
Stopped (Business): “Due to corporate strategic adjustment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA/GPRC5D dual CAR-T | Cell therapy | 3e+06 cells/kg | — |
| Subject | BCMA/GPRC5D dual CAR-T | Cell therapy | 1e+07 cells/kg | — |